Literature DB >> 23885114

Clinical guideline for pharmacological management of cancer pain: the Japanese Society of Palliative Medicine recommendations.

Takashi Yamaguchi1, Yasuo Shima, Tatsuya Morita, Miki Hosoya, Motohiro Matoba.   

Abstract

Pain is the most frequent and distressing symptom in cancer patients. As part of a worldwide effort to improve the quality of pain control, several clinical guidelines for the management of cancer pain have been published and revised in the last decade. The Japanese Society of Palliative Medicine first published a Japanese clinical guideline for the management of cancer pain in 2000. Since then, many clinical studies concerning cancer pain management have been conducted, new drugs have become available in Japan and the methodology of developing a guideline has been refined. Therefore, we decided to develop a novel clinical guideline. This review paper summarizes the recommendations and the rationales of this new clinical guideline for the pharmacological management of cancer pain. In addition, a short summary of the clinical guideline development process is provided. This new Japanese Society of Palliative Medicine guideline highlights the importance of conducting well-designed studies to identify the best practices in cancer pain management.

Entities:  

Keywords:  cancer pain; guideline; nonopioid analgesics; opioid analgesics

Mesh:

Substances:

Year:  2013        PMID: 23885114     DOI: 10.1093/jjco/hyt099

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  8 in total

1.  Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial.

Authors:  Naohito Shimoyama; Ikuo Gomyo; Nobuyuki Katakami; Masakuni Okada; Nobuyuki Yukitoshi; Eri Ohta; Megumi Shimoyama
Journal:  Int J Clin Oncol       Date:  2014-05-20       Impact factor: 3.402

2.  Effect of Prophylactic Anti-emetics on Opioid-induced Nausea and Vomiting: A Retrospective Observational Cohort Study.

Authors:  Tomoki Tamura; Keita Kawakado; G O Makimoto; Masamoto Nakanishi; Shoichi Kuyama
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

3.  A Framework for Incorporating Patient Preferences to Deliver Participatory Medicine via Interdisciplinary Healthcare Teams.

Authors:  Craig Kuziemsky; Davood Astaraky; Szymon Wilk; Wojtek Michalowski; Pavel Andreev
Journal:  AMIA Annu Symp Proc       Date:  2014-11-14

Review 4.  Quality Assessment of Cancer Pain Clinical Practice Guidelines.

Authors:  Zhigang Zhang; Xiao Cao; Qi Wang; Qiuyu Yang; Mingyao Sun; Long Ge; Jinhui Tian
Journal:  Front Oncol       Date:  2022-05-27       Impact factor: 5.738

5.  Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.

Authors:  Keiichiro Imanaka; Yushin Tominaga; Mila Etropolski; Hiroki Ohashi; Keiichiro Hirose; Taka Matsumura
Journal:  Clin Drug Investig       Date:  2014-07       Impact factor: 2.859

6.  Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study.

Authors:  Seong Hoon Shin; Ho Sup Lee; Yang Soo Kim; Young Jin Choi; Sung Hyun Kim; Hyuk Chan Kwon; Sung Yong Oh; Jung Hun Kang; Chang Hak Sohn; Sang Min Lee; Jin Ho Baek; Young Joo Min; Choongrak Kim; Joo Seop Chung
Journal:  Cancer Res Treat       Date:  2014-07-21       Impact factor: 4.679

Review 7.  Guidelines for prescribing opioids for chronic non-cancer pain in Korea.

Authors:  Eung Don Kim; Jin Young Lee; Ji Seon Son; Gyeong Jo Byeon; Jin Seok Yeo; Do Wan Kim; Sie Hyeon Yoo; Ji Hee Hong; Hue Jung Park
Journal:  Korean J Pain       Date:  2016-12-30

8.  Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies.

Authors:  Yoji Saito; Takaaki Yokota; Masatsugu Arai; Yukio Tada; Masahiko Sumitani
Journal:  J Pain Res       Date:  2018-12-24       Impact factor: 3.133

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.